As of July 26, 2026, 21 CFR 216.23 lists six substances that can be used through this pathway: Brilliant Blue G, cantharidin for topical use only, diphenylcyclopropenone for topical use only, N-acetyl-D-glucosamine for topical use only, squaric acid dibutyl ester for topical use only, and thymol iodide for topical use only
Seek immediate medical attention (call 999 or attend A&E) if experiencing: Seizures or convulsions of any type, particularly if this is a new occurrence Loss of consciousness or fainting episodes Severe, sudden-onset headache unlike previous headaches, especially if accompanied by visual changes, neck stiffness, or confusion Symptoms suggestive of stroke , including sudden weakness, speech difficulties, facial drooping, or visual disturbances Severe hypoglycaemia symptoms with confusion, inability to concentrate, or altered consciousness (particularly relevant for patients on insulin or sulphonylureas) Severe, persistent abdominal pain (especially if radiating to the back) stop taking Wegovy and seek urgent medical attention as this could indicate pancreatitis Contact your GP or prescribing clinician within 24 hours for: Persistent or worsening headaches that do not respond to simple analgesia Recurrent dizziness affecting daily activities or balance Visual disturbances including blurred vision or changes in vision (noting that diabetic retinopathy complications have been reported with rapid glycaemic improvement) Unexplained confusion or cognitive changes Severe, persistent gastrointestinal symptoms (vomiting, diarrhoea) that may lead to dehydration If you need urgent advice and it's not life-threatening, contact NHS 111
J3420 Medicare reimbursement rates and fee schedule Medicare Part B reimburses J3420 under the Average Sales Price (ASP) methodology at ASP plus 6%
BioDrugs 34, 1126
"Wegovy for Weight Loss: Uses, Side Effects, Dosage." STEP 1 trial: 14.9% mean weight loss
